313397-13-6
313397-13-6
Chemical Structure
Reversan
Synonym(s): CBLC4H10
- CAS No.: 313397-13-6
- Formula:C26H27N5O2
- Molecular Weight:441.52
IUPAC Name: N-(3-morpholinopropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide
InChIKey: JTRXWCLQFAZHGP-UHFFFAOYSA-N
SMILES: O=C(C1=C2N(C(C3=CC=CC=C3)=CC(C4=CC=CC=C4)=N2)N=C1)NCCCN5CCOCC5
Biological Activity: Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1), and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Reversan | 99.57% | Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1), and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Reversan (Standard) | ≥98% | Reversan (Standard) is the analytical standard of Reversan (HY-107643). This product is intended for research and analytical applications. Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1), and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tivnan A, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 2015;9:218. Published 2015 Jun 16. [Content Brief]
-
[2]. Catherine A Burkhart, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res
. 2009 Aug 15;69(16):6573-80. [Content Brief]
Keywords
